| 高诗琦,赵 曙.核输出蛋白1抑制剂塞利尼索在淋巴瘤中研究进展[J].肿瘤学杂志,2024,30(7):604-610. |
| 核输出蛋白1抑制剂塞利尼索在淋巴瘤中研究进展 |
| Research Progress on Exportin 1 Inhibitor Selinexor in Treatment of Lymphoma |
| 投稿时间：2024-03-25 |
| DOI：10.11735/j.issn.1671-170X.2024.07.B011 |
|
 |
| 中文关键词: 选择性核输出蛋白抑制剂 核输出蛋白1 塞利尼索 淋巴瘤 靶向治疗 |
| 英文关键词:selective inhibitor of nuclear export exportin 1 selinexor lymphoma targeted therapy |
| 基金项目:哈尔滨医科大学肿瘤医院海燕基金（JJZD2022-10）；北京医学奖励基金会（YXJL-2020-0785-1072） |
|
| 摘要点击次数: 347 |
| 全文下载次数: 92 |
| 中文摘要: |
| 摘 要：核输出蛋白1（exportin 1，XPO1）是一种细胞中主要的核输出蛋白，负责大量蛋白质以及多种RNA由胞核到胞质的输出。XPO1在多种恶性肿瘤中过表达，并导致调节蛋白在细胞内分布不均、肿瘤细胞增殖失控。因此，靶向XPO1迅速成为多种癌症的一种潜在治疗方法。塞利尼索是全球首个上市的XPO1抑制剂，在多种实体瘤及血液恶性肿瘤中表现出优异的抗肿瘤活性，美国食品药品监督管理局已批准其用于复发性/难治性多发性骨髓瘤及弥漫大B细胞淋巴瘤的治疗。全文就塞利尼索在淋巴瘤中临床前研究和临床研究的应用进展进行综述。 |
| 英文摘要: |
| Abstract： Exportin 1(XPO1) is a major nuclear export protein in cells， responsible for the exporting a large number of proteins and RNA from the nucleus to the cytoplasm. XPO1 is overexpressed in various malignant tumors， leading to uneven distribution of regulatory proteins within cells and uncontrolled tumor cell proliferation. Therefore， XPO1 would be a potential target for treatment of multiple types of cancer. Selinexor is the first marketed XPO1 inhibitor， exhibiting an excellent antitumor activity in various solid tumors and hematological malignancies. The US Food and Drug Administration has approved its use for the treatment of relapse and /or refractory multiple myeloma and diffuse large B-cell lymphoma. This paper reviews the current status of preclinical research and clinical application of selinexor in treatment for lymphoma. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |